Wall Street analysts expect that Affimed NV (NASDAQ:AFMD) will announce $1.15 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Affimed’s earnings. The highest sales estimate is $1.74 million and the lowest is $560,000.00. Affimed reported sales of $1.48 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 22.3%. The firm is scheduled to report its next quarterly earnings report on Thursday, March 29th.
On average, analysts expect that Affimed will report full-year sales of $1.15 million for the current fiscal year, with estimates ranging from $1.80 million to $10.00 million. For the next financial year, analysts forecast that the business will post sales of $17.64 million per share, with estimates ranging from $2.28 million to $33.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Affimed.
Affimed (NASDAQ:AFMD) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.21). Affimed had a negative return on equity of 72.94% and a negative net margin of 1,074.37%.
A number of large investors have recently added to or reduced their stakes in AFMD. Point72 Asset Management L.P. purchased a new stake in Affimed in the third quarter worth $658,000. Dimensional Fund Advisors LP increased its position in Affimed by 817.9% in the third quarter. Dimensional Fund Advisors LP now owns 137,783 shares of the biopharmaceutical company’s stock worth $310,000 after buying an additional 122,773 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in Affimed in the second quarter worth $144,000. Finally, Nationwide Fund Advisors increased its position in Affimed by 4.6% in the second quarter. Nationwide Fund Advisors now owns 506,199 shares of the biopharmaceutical company’s stock worth $1,038,000 after buying an additional 22,172 shares during the last quarter. 40.34% of the stock is owned by institutional investors and hedge funds.
Affimed (NASDAQ:AFMD) traded down $0.05 during trading hours on Thursday, reaching $1.25. The company’s stock had a trading volume of 84,900 shares, compared to its average volume of 170,845. The company has a quick ratio of 6.39, a current ratio of 6.43 and a debt-to-equity ratio of 0.14. Affimed has a twelve month low of $1.15 and a twelve month high of $2.95. The stock has a market capitalization of $58.07, a P/E ratio of -1.60 and a beta of 3.48.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.